Remove 2014 Remove Leads Remove Networking
article thumbnail

Targeting ovarian cancer with a novel antibody therapeutic

European Pharmaceutical Review

AbbVie has leading positions in haematology oncology treatments with BTK and BCL-2 inhibitors as foundational therapies in CLL and other blood cancers. While at Roche, she also held various positions, such as Global Medical Lead in Oncology in Switzerland and Medical Manager in Brazil. National Comprehensive Cancer Network.

Medical 98
article thumbnail

$8 million grant awarded to new US stem cell clinic

European Pharmaceutical Review

The Cedars-Sinai Board of Governors Regenerative Medicine Institute and the Smidt Heart Institute will lead the project. The advanced facility will be based on the Regenerative Medicine Clinic established at Cedars-Sinai in 2014, developing clinical trials for neurological, cardiovascular, musculoskeletal and autoimmune diseases.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

article thumbnail

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Legacy MEDSearch

Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. Cala Health’s products are the only FDA-cleared, clinically validated non-invasive devices for the relief of hand tremors so patients with essential tremor can return to the moments that matter.

article thumbnail

The U.S. health insurance market is undergoing a post-pandemic sea change

Clarivate

Insurance exchanges underwent their largest single-year enrollment growth since their inception in 2014, pushing exchange enrollment to yet another all-time high. This may also lead to gaps in care, reduced drug adherence, increased emergency room visits and a decline in chronic care management. The post The U.S.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

We start our meetings by bringing to life a patient testimony and asking the team to reflect on how the goal of each meeting ultimately leads back to the needs of patients,” Chiesi says. “If Chiesi’s broad efforts focus on serving the global patient community, but patient centricity within the organisation also happens on a personal level. “We

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

After all, around a third of the world’s leading life sciences corporations have their headquarters in the country. Locating a subsidiary in close proximity to such an institution has advantages beyond pipeline talent, as there is the potential to access research and tap into networks for product development and clinical trials.